AR075874A1 - Derivados de indazol inhibidores de hsp90 composiciones que los contienen y utilizacion - Google Patents
Derivados de indazol inhibidores de hsp90 composiciones que los contienen y utilizacionInfo
- Publication number
- AR075874A1 AR075874A1 ARP100100858A ARP100100858A AR075874A1 AR 075874 A1 AR075874 A1 AR 075874A1 AR P100100858 A ARP100100858 A AR P100100858A AR P100100858 A ARP100100858 A AR P100100858A AR 075874 A1 AR075874 A1 AR 075874A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- radicals
- chosen
- alkoxy
- radical
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003254 radicals Chemical class 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- -1 hydroxy, mercapto , amino Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000003282 alkyl amino group Chemical group 0.000 abstract 5
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 5
- 239000004472 Lysine Substances 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 150000003857 carboxamides Chemical class 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 2
- 239000011707 mineral Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 150000007530 organic bases Chemical class 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Derivados de indazol, utiles como medicamentos para cáncer. Reivindicacion 1: Productos de formula (1) en la que R4 representa H, CH3, CH2CH3, CF3, F, Cl, Br, I; Het representa un heterociclo aromático o parcialmente insaturado -de tipo dihidro o tetrahidro- mono o bicíclico, de 5 a 11 miembros, que contiene de 1 a 4 heteroátomos, elegidos entre N, O o S, opcionalmente sustituido por uno o varios radicales R1 o R'1 iguales o diferentes, tal como se describe a continuacion; R se elige del grupo constituido por las formulas (A) a (E) donde R1 y/o R'1, iguales o diferentes, se eligen del grupo constituido por H, halogeno, CF3, nitro, ciano, alquilo, hidroxi, mercapto, amino, alquilamino, dialquilamino, alcoxi, alquiltio, carboxi libre o esterificado por un radical alquilo, carboxamida, CO-NH(alquilo), CON(alquilo)2, NH-CO-alquilo, sulfonamida, NH-SO2-alquilo, S(O)2-NH-alquilo, S(O2)-N(alquilo)2, estando todos los radicales alquilo, alcoxi y alquiltio opcionalmente sustituidos por uno o varios radicales iguales o diferentes, elegido(s) entre: halogeno, hidroxi, alcoxi, amino, alquilamino y dialquilamino; W1, W2, W3 representan independientemente CH o N; X representa un átomo de oxígeno o de azufre o un radical NR2, C(O), S(O) o S(O)2; V representa un átomo de hidrogeno o un átomo de halogeno o un radical -O-R2 o un radical -NH-R2 en el que R2 representa un átomo de hidrogeno o un radical alquilo C1-6, cicloalquilo C3-8 o heterocicloalquilo C3-10, mono o bicíclico; estando estos radicales alquilo, cicloalquilo y heterocicloalquilo opcionalmente sustituidos por uno o varios radicales iguales o diferentes elegido(s) entre los radicales: i) O-PO3H2; -O-PO3Na2; -O-SO3H2; -O-SO3Na2; -O-CH2-PO3H2; -O-CH2-PO3Na2; -O-CO-alanina; -O-CO-glicina; -O-CO-serina; -O-CO-lisina; -O-CO-arginina; -O-CO-glicina-lisina; -O-CO-alanina-lisina; ii) halogeno; hidroxi; mercapto; amino; carboxamida (CONH2); carboxi; iii) heterocicloalquilo; cicloalquilo; heteroarilo; carboxi esterificado por un radical alquilo; CO-NH(alquilo); -O-CO-alquilo; -NH-CO-alquilo; alquilo; alcoxi; alquiltio; alquilamino; dialquilamino; estando, en todos estos ultimos radicales, los radicales alquilo, alcoxi y alquiltio ellos mismos sustituidos opcionalmente con uno o más radicales iguales o diferentes elegidos entre los radicales hidroxi, mercapto, amino, alquilamino, dialquilamino, CO2-alquilo, NHCO2-alquilo y heterocicloalquilo; estando en todos estos radicales, los radicales cicloalquilo, heterocicloalquilo y heteroarilo ellos mismos opcionalmente sustituidos con uno o varios radicales, iguales o diferentes, elegido(s) entre los radicales hidroxi, alquilo, alcoxi, CH2OH; amino, alquilamino, dialquilamino, CO2-alquilo o NHCO2-alquilo; estando dichos productos de formula (1) en todas las formas tautomeras e isomeras posibles, racémicos, enantiomeros y diastereoisomeros, así como sales de adicion con ácidos minerales y orgánicos o con bases minerales y orgánicas de productos de formula (1), así como profármacos de productos de formula (1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0901274A FR2943341B1 (fr) | 2009-03-19 | 2009-03-19 | Nouveaux derives d'indazole inhibiteurs d'hsp90,compositions les contenant et utilisation |
| FR1050341A FR2955323B1 (fr) | 2010-01-19 | 2010-01-19 | Nouveaux derives d'indazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075874A1 true AR075874A1 (es) | 2011-05-04 |
Family
ID=42313103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100858A AR075874A1 (es) | 2009-03-19 | 2010-03-18 | Derivados de indazol inhibidores de hsp90 composiciones que los contienen y utilizacion |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20120010241A1 (es) |
| EP (1) | EP2408762A1 (es) |
| JP (1) | JP2012520859A (es) |
| KR (1) | KR20110128942A (es) |
| CN (1) | CN102439003A (es) |
| AR (1) | AR075874A1 (es) |
| AU (1) | AU2010224652A1 (es) |
| BR (1) | BRPI1009375A2 (es) |
| CA (1) | CA2755660A1 (es) |
| IL (1) | IL215139A0 (es) |
| MX (1) | MX2011009806A (es) |
| RU (1) | RU2011142151A (es) |
| SG (1) | SG174466A1 (es) |
| TW (1) | TW201038553A (es) |
| UY (1) | UY32505A (es) |
| WO (1) | WO2010106290A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101609412B1 (ko) * | 2009-07-10 | 2016-04-05 | 다이호야쿠힌고교 가부시키가이샤 | 아자 2 고리형 화합물 또는 그 염 |
| BR112013017416A2 (pt) | 2011-01-07 | 2019-09-24 | Taiho Pharmaceutical Co Ltd | derivado de indola ou indazola ou sal do mesmo |
| KR20140025327A (ko) * | 2011-01-07 | 2014-03-04 | 다이호야쿠힌고교 가부시키가이샤 | 신규 2 고리형 화합물 또는 그 염 |
| US20150051203A1 (en) * | 2012-03-28 | 2015-02-19 | Synta Pharmaceuticals Corp. | Triazole derivatives as hsp90 inhibitors |
| EP2882715B1 (en) * | 2012-05-18 | 2016-11-09 | Sanofi | Pyrazole derivatives and their use as lpar5 antagonists |
| WO2014121062A1 (en) * | 2013-02-01 | 2014-08-07 | Acetylon Pharmaceuticals, Inc. | Selective hdac3 inhibitors |
| DE102017008073A1 (de) * | 2017-08-28 | 2019-02-28 | Henkel Ag & Co. Kgaa | Neue anionische Tenside und Wasch- und Reinigungsmittel, welche diese enthalten |
| CN117003754B (zh) * | 2022-04-28 | 2025-07-25 | 腾讯科技（深圳）有限公司 | 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6353007B1 (en) * | 2000-07-13 | 2002-03-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents |
| WO2003027085A2 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors |
| US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| NZ588960A (en) * | 2005-02-25 | 2012-06-29 | Serenex Inc | Tetrahydroindolone and tetrahydroindazolone derivatives |
| JP2007145786A (ja) * | 2005-11-30 | 2007-06-14 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| MX2008010671A (es) * | 2006-02-21 | 2008-10-01 | Amgen Inc | Derivados de cinolina como inhibidores de fosfodiesterasa 10. |
| WO2007114763A1 (en) * | 2006-03-31 | 2007-10-11 | Astrazeneca Ab | Sulphonamide derivates as modulators of the glucocorticoid receptor |
| WO2008024977A2 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Isoquinoline, quinazoline and phthalazine derivatives |
-
2010
- 2010-03-18 CN CN2010800219733A patent/CN102439003A/zh active Pending
- 2010-03-18 JP JP2012500297A patent/JP2012520859A/ja active Pending
- 2010-03-18 RU RU2011142151/04A patent/RU2011142151A/ru not_active Application Discontinuation
- 2010-03-18 US US13/257,516 patent/US20120010241A1/en not_active Abandoned
- 2010-03-18 KR KR1020117024518A patent/KR20110128942A/ko not_active Withdrawn
- 2010-03-18 WO PCT/FR2010/050483 patent/WO2010106290A1/fr not_active Ceased
- 2010-03-18 BR BRPI1009375A patent/BRPI1009375A2/pt not_active IP Right Cessation
- 2010-03-18 AR ARP100100858A patent/AR075874A1/es not_active Application Discontinuation
- 2010-03-18 EP EP10715951A patent/EP2408762A1/fr not_active Withdrawn
- 2010-03-18 AU AU2010224652A patent/AU2010224652A1/en not_active Abandoned
- 2010-03-18 SG SG2011067634A patent/SG174466A1/en unknown
- 2010-03-18 CA CA2755660A patent/CA2755660A1/fr not_active Abandoned
- 2010-03-18 MX MX2011009806A patent/MX2011009806A/es not_active Application Discontinuation
- 2010-03-18 TW TW099108049A patent/TW201038553A/zh unknown
- 2010-03-19 UY UY0001032505A patent/UY32505A/es not_active Application Discontinuation
-
2011
- 2011-09-14 IL IL215139A patent/IL215139A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY32505A (es) | 2010-10-29 |
| TW201038553A (en) | 2010-11-01 |
| BRPI1009375A2 (pt) | 2016-03-15 |
| MX2011009806A (es) | 2011-09-29 |
| AU2010224652A1 (en) | 2011-10-13 |
| WO2010106290A1 (fr) | 2010-09-23 |
| JP2012520859A (ja) | 2012-09-10 |
| IL215139A0 (en) | 2011-12-29 |
| EP2408762A1 (fr) | 2012-01-25 |
| CN102439003A (zh) | 2012-05-02 |
| KR20110128942A (ko) | 2011-11-30 |
| SG174466A1 (en) | 2011-10-28 |
| RU2011142151A (ru) | 2013-04-27 |
| CA2755660A1 (fr) | 2010-09-23 |
| US20120010241A1 (en) | 2012-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075874A1 (es) | Derivados de indazol inhibidores de hsp90 composiciones que los contienen y utilizacion | |
| ECSP10010473A (es) | Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| NI201000198A (es) | Compuestos triazina como inhibidores mtor y quinasa p13. | |
| AR072510A1 (es) | Derivados de triazinas y de uracilos, su preparacion y su aplicacion en terapeutica humana | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| CO6210698A2 (es) | Compuestos quimicos 637:piridopirimidindionas como inhibidores de pde4 | |
| AR059590A1 (es) | Inhibidores de quinasa basados en la hidantoina | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR083180A1 (es) | Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| AR072820A1 (es) | Derivados de imidazo[1,2-a]pirimidina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| CL2012000003A1 (es) | Compuestos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida sustituida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y uso de dichos compuestos como inhibidores de fosforilacion de akt (pkb) para el tratamiento del cancer. | |
| AR104331A1 (es) | Derivados de tetrazol | |
| CR20130476A (es) | Derivados de pirazolidin-3-ona | |
| AR105662A1 (es) | Derivados de piridina y de pirimidina como inhibidores del eaat3 | |
| AR075251A1 (es) | Derivados de 6-(6-sustituido-triazolopiridazina-sulfanil)-5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles, metodo de preparacion e intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del cancer y otros trastorno hiperproliferativos. | |
| AR105327A1 (es) | Derivados de imidazol | |
| AR077405A1 (es) | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer | |
| CO5650235A2 (es) | Derivados de imidazol | |
| PE20120576A1 (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion farmaceuticamente aceptable |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |